Publications

Selected Publications (last 10 years)

 1:  Zhang Y, Ikegami T, Honda A, Miyazaki T, Bouscarel B, Rojkind M, Hyodo I, Matsuzaki Y. Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats.
Hepatology. 2006, Sep; 44(3):612-22.

 2:  Ikegami T, Krilov L, Meng J, Patel B, Chapin-Kennedy K, Bouscarel B. Decreased glucagon responsiveness by bile acids: a role for protein kinase Calpha and glucagon receptor phosphorylation.
Endocrinology. 2006, Nov; 147(11):5294-302.  

3:  Le M, Krilov L, Meng J, Chapin-Kennedy K, Ceryak S, Bouscarel B. Bile acids stimulate PKCalpha autophosphorylation and activation: role in the attenuation of prostaglandin E1-induced cAMP production in human dermal fibroblasts.
Am J Physiol Gastrointest Liver Physiol. 2006, Aug; 291(2):G275-87.

4:  Meng JP, Ceryak S, Aratsu Z, Jones L, Epstein L, Bouscarel B. Biphasic regulation by bile acids of dermal fibroblast proliferation through regulation of cAMP production and COX-2 expression level.
Am J Physiol Cell Physiol. 2006, Sep; 291(3):C546-54.  

5:  Ikegami T, Matsuzaki Y, Al Rashid M, Ceryak S, Zhang Y, Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid.
Mol Cancer Ther. 2006, Jan; 5(1):68-79.

 6:  Miyazaki T, Karube M, Matsuzaki Y, Ikegami T, Doy M, Tanaka N, Bouscarel B. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis.
J Hepatol. 2005, Jul; 43(1):117-25.

 7:  Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.
Hepatology. 2005, Apr; 41(4):896-905.  

8:  Miyazaki T, Matsuzaki Y, Ikegami T, Miyakawa S, Doy M, Tanaka N, Bouscarel B. Optimal and effective oral dose of taurine to prolong exercise performance in rat.
Amino Acids. 2004, Dec; 27(3-4):291-8.  

9:  Miyazaki T, Matsuzaki Y, Ikegami T, Miyakawa S, Doy M, Tanaka N, Bouscarel B. The harmful effect of exercise on reducing taurine concentration in the tissues of rats treated with CCl4 administration.
J Gastroenterol. 2004, Jun; 39(6):557-62.  

10:  Miyazaki T, Matsuzaki Y, Karube M, Bouscarel B, Miyakawa S, Tanaka N. Amino acid ratios in plasma and tissues in a rat model of liver cirrhosis before and after exercise.
Hepatol Res. 2003, Nov; 27(3):230-237.  

11:  Matsuzaki Y, Miyazaki T, Ohkoshi N, Miyakawa S, Bouscarel B, Tanaka N. Degeneration of skeletal muscle fibers in the rat administrated carbon tetrachloride: similar histological findings of the muscle in a 64-year-old patient of LC with muscle cramp.
Hepatol Res. 2002, Dec; 24(4):368-378.

12:  Matsuzaki Y, Bouscarel B, Ikegami T, Honda A, Doy M, Ceryak S, Fukushima S, Yoshida S, Shoda J, Tanaka N. Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver.
Biochim Biophys Acta. 2002, Nov 20; 1588(2):139-48.  

13:  Matsuzaki Y, Miyazaki T, Miyakawa S, Bouscarel B, Ikegami T, Tanaka N. Decreased taurine concentration in skeletal muscles after exercise for various durations.
Med Sci Sports Exerc. 2002, May; 34(5):793-7.

 14:  Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Cancer Res. 2002, Jan 1; 62(1):179-87.

 15:  Ikegami T, Cypess AM, Bouscarel B. Modulation of glucagon receptor expression and response in transfected human embryonic kidney cells.
Am J Physiol Cell Physiol. 2001, Oct; 281(4):C1396-402.  

16:  Kobayashi K, Ceryak S, Matsuzaki Y, Kudoh S, Bouscarel B. Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Biochim Biophys Acta. 2001, Feb 16; 1525(1-2):125-9.

 17:  Ceryak S, Bouscarel B, Malavolti M, Robins SJ, Caslow KL, Fromm H. Effect of ursodeoxycholic acid on hepatic LDL binding and uptake in dietary hypercholesterolemic hamsters.
Atherosclerosis. 2000, Nov; 153(1):59-67.  

18:  Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Int J Cancer. 1999, Nov 12; 83(4):491-6.  

19:  Bouscarel B, Kroll SD, Fromm H. Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Gastroenterology. 1999, Aug; 117(2):433-52. Review.

20:  Bouscarel B, Matsuzaki Y, Le M, Gettys TW, Fromm H. Changes in G protein expression account for impaired modulation of hepatic cAMP formation after BDL.
Am J Physiol. 1998, Jun; 274(6 Pt 1):G1151-9.  

21:  Bouscarel B, Noonan F, Ceryak S, Gettys TW, Phillips TM, DeFabo EC. Regulation of stimulated cyclic AMP synthesis by urocanic acid.
Photochem Photobiol. 1998, Mar; 67(3):324-31.  

22:  IJland SA, Noonan FP, Ceryak S, Steenvoorden DP, Bouscarel B, Hug D, Beijersbergen van Henegouwen GM, De Fabo EC. Urocanic acid does not photobind to DNA in mice irradiated with immunosuppressive doses of UVB.
Photochem Photobiol. 1998, Feb; 67(2):222-6.

 23:  Ceryak S, Bouscarel B, Malavolti M, Fromm H. Extrahepatic deposition and cytotoxicity of lithocholic acid: studies in two hamster models of hepatic failure and in cultured human fibroblasts.
Hepatology. 1998, Feb; 27(2):546-56.

 24:  Matsuzaki Y, Bouscarel B, Le M, Ceryak S, Gettys TW, Shoda J, Fromm H. Effect of cholestasis on regulation of cAMP synthesis by glucagon and bile acids in isolated hepatocytes.
Am J Physiol. 1997, Jul; 273(1 Pt 1):G164-74.

25:  Bouscarel B, Reza S, Dougherty LA, Fromm H, Nussbaum R. Regulation of taurocholate and ursodeoxycholate uptake in hamster hepatocytes by Ca(2+)-mobilizing agents.
Am J Physiol. 1996, Dec; 271(6 Pt 1):G1084-95.  

26:  Bouscarel B, Ceryak S, Fromm H.  Comparative effect of ursodeoxycholic acid and calcium antagonists on the binding, uptake and degradation of LDL in isolated hamster hepatocytes.
Biochim Biophys Acta. 1996, Jun 11; 1301(3):230-6.